Archemix Corporation
148 Sidney Street
Cambridge
Massachusetts
02139
United States
Tel: 617-621-7700
Fax: 617-621-9300
Website: http://www.archemix.com/
Email: info@archemix.com
41 articles about Archemix Corporation
-
Geron Corporation: A Tribute to Alex Barkas
11/23/2011
-
Baxter International, Inc. Announces Acquisition of All Hemophilia-Related Assets of Archemix Corporation and an Exclusive License of Its Anti-TFPI Aptamer Technology for $30 Million Upfront Plus Possible $285 Million More in Milestones
11/19/2010
-
miRagen Therapeutics and Archemix Corporation to Collaborate on Conjugated Aptamer-microRNA Therapeutics
7/23/2009
-
Archemix Corporation and Dicerna Pharmaceuticals to Collaborate on Conjugated Aptamer-Dicer Substrate RNAi Therapeutics
7/21/2009
-
Archemix Corporation Appoints Ken Bate as President and Chief Executive Officer
5/6/2009
-
Archemix Corporation Initiates Phase 2a for Lead Aptamer Product Candidate ARC1779
3/30/2009
-
Archemix Corporation Merger with NitroMed, Inc. Falls Through
1/28/2009
-
Archemix Corporation Announces Continued Progress with Business Strategy
1/27/2009
-
GlaxoSmithKline (JOBS) and Archemix Corporation Form Strategic Alliance Worth $1.4 Billion to Develop Aptamers to Treat Inflammatory Diseases
12/23/2008
-
Archemix Corporation Announces ARC1779 Data to Be Presented at Upcoming American Society of Hematology Annual Meeting, December 6-9, 2008
12/4/2008
-
NitroMed, Inc. and Archemix Corporation Announce Merger Agreement
11/19/2008
-
Archemix Corporation Signs Aptamer Therapeutics Agreement With Eli Lilly and Company
10/20/2008
-
Archemix Corporation to Present at the 28th Annual Canaccord Adams Global Growth Conference
8/12/2008
-
Archemix Corporation Expands Collaboration with Ribomic, Inc. for Rights to Develop Aptamer Therapeutics for Multiple Drug Targets; Archemix Will Receive an Upfront Payment of $6 Million with a Total Potential Payment of $200M
8/8/2008
-
Archemix Corporation's ARC1779 Granted Orphan Designation in EU for the Treatment of TTP, a Life-Threatening Blood Disorder
7/7/2008
-
Archemix Corporation's ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
4/22/2008
-
Archemix Corporation Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood Disorder
3/17/2008
-
Archemix Corporation CEO to Present at the 28th Annual Cowen and Company Health Care Conference
3/13/2008
-
Archemix Corporation Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Ophthotech
2/19/2008
-
Archemix Corporation and NascaCell Expand Strategic Alliance for Aptamer-Based Drug Discovery
2/12/2008